

IASLC WCLC 2018 Industry Supported Symposium

New Insights and Clinical Implications for the Treatment of ALK+ NSCLC



Breakfast to be provided

Sunday, September 23, 2018

9:45 AM – 11:15 AM

Room 105, North Building,
Metro Toronto Convention Centre (MTCC)
Toronto, Canada

This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.

This medical symposium is developed and funded by Takeda Oncology. Takeda Oncology is a trademark of Takeda Pharmaceutical Company Limited. Millennium Pharmaceuticals, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. ©2018 Millennium Pharmaceuticals, Inc. OMS/ONC/18/0084



ONCOLOGY

New Insights and Clinical Implications for the Treatment of ALK+ NSCLC

FACULTY

Chair:

Natasha Leigh, MD, MMSc (Clin Epi), FRCPC, FASCO

*Princess Margaret Cancer Centre
Toronto, Ontario, Canada*

Robert C. Doebele, MD, PhD

*University of Colorado Cancer Center
Colorado, USA*

Karen Reckamp, MD

*City of Hope Comprehensive
Cancer Center
California, USA*

Luis Paz-Ares, MD, PhD

*Hospital Universitario Doce de Octubre
Madrid, Spain*

AGENDA

9:45 AM - 9:52 AM Welcome and Introductions

7 min Natasha Leigh, MD, MMSc (Clin Epi), FRCPC, FASCO

9:52 AM - 10:14 AM Insights Into Mechanisms of Resistance and Characterizing Oncogenic Drivers in ALK+ NSCLC

22 min Robert C. Doebele, MD, PhD

10:14 AM - 10:36 AM Current Landscape of ALK Inhibitors and Key Data

22 min Karen Reckamp, MD

10:36 AM - 10:58 AM How to Integrate New Agents and Disease Monitoring Practices Into Optimal Patient Care

22 min Luis Paz-Ares, MD, PhD

10:58 AM - 11:13 AM Panel Discussion

15 min Faculty

11:13 AM - 11:15 AM Conclusion

2 min Natasha Leigh, MD, MMSc (Clin Epi), FRCPC, FASCO
